BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc.
Your view on BBOT
Overview
What the company does, where it operates, and who runs it.
About BridgeBio Oncology Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Eli Wallace
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Eli Wallace
- Headquarters
- US
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors.
Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways.
The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BridgeBio Oncology Therapeutics Inc., and the rating behind it. BBOT last traded at $4.95; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BridgeBio Oncology Therapeutics Inc.. Starting points for BridgeBio Oncology Therapeutics Inc.: EPS -$2274.89, beta 0.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BridgeBio Oncology Therapeutics Inc.. BridgeBio Oncology Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BridgeBio Oncology Therapeutics Inc.. Trailing twelve-month EPS for BridgeBio Oncology Therapeutics Inc. stands at -$2274.89. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BridgeBio Oncology Therapeutics Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BridgeBio Oncology Therapeutics Inc. valued side by side against its closest peers. BridgeBio Oncology Therapeutics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BridgeBio Oncology Therapeutics Inc., and how their positions are changing. At a $396.5M market value, institutional positions materially move BridgeBio Oncology Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BridgeBio Oncology Therapeutics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BridgeBio Oncology Therapeutics Inc.. BridgeBio Oncology Therapeutics Inc. is a $396.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BridgeBio Oncology Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BridgeBio Oncology Therapeutics Inc.. Coverage tracks BridgeBio Oncology Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.